Effects of Sacubitril/Valsartan on Survival in Patients with Heart Failure and Significant Valvular Heart Disease

射血分数 沙库比林 缬沙坦 内科学 医学 心力衰竭 心脏病学 危险系数 相伴的 比例危险模型 置信区间 血压
作者
Donna Shu‐Han Lin,Ying‐Ting Chao,Shu‐Lin Chuang,Jen‐Kuang Lee,Ting‐Tse Lin,Lung‐Chun Lin,Kuan‐Chih Huang,Juey‐Jen Hwang
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
标识
DOI:10.1002/cpt.3417
摘要

Although the benefits of sacubitril/valsartan in heart failure with reduced ejection fraction (HFrEF) are well established, patients with hemodynamically significant mitral regurgitation (MR) were excluded from pivotal trials. We aimed to assess the effects of sacubitril/valsartan on survival in patients with HFrEF and concomitant significant MR. All patients from a single center who underwent echocardiography between June 2008 and December 2020, with a left ventricular ejection fraction (LVEF) of less than 40% and hemodynamically significant MR were recruited. Patients were categorized according to drug use and year of the index echocardiogram into the angiotensin receptor/neprilysin inhibitor (ARNI), non‐ARNI before 2017, and non‐ARNI after 2017 groups. Patients in the ARNI and non‐ARNI after 2017 groups were compared directly, whereas patients in the non‐ARNI before 2017 group were matched to the ARNI group in a 3:1 ratio. The outcome of interest was all‐cause mortality. Death was compared between the groups using univariate and multivariate Cox proportional hazard models. After exclusion by criteria and matching, there remained 610 patients in the ARNI group, 434 in the non‐ARNI after 2017 group, and 1,722 in the non‐ARNI before 2017 group. During follow‐up, all‐cause mortality was significantly lower in the ARNI group compared with both non‐ARNI after 2017 and non‐ARNI before 2017 groups. Multivariate analysis of both pairs of comparison between groups found the use of ARNI to be significantly associated with increased survival. In patients with HFrEF and concomitant significant MR, treatment with sacubitril/valsartan was associated with lower risks of all‐cause death.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夏瑾完成签到 ,获得积分10
1秒前
zhihaijun完成签到,获得积分10
1秒前
成就映之完成签到,获得积分10
1秒前
3秒前
ASASAS完成签到,获得积分10
3秒前
4秒前
Fox完成签到,获得积分0
4秒前
M二以完成签到,获得积分10
5秒前
迷路的忆梅完成签到,获得积分10
6秒前
坦率的匪发布了新的文献求助10
6秒前
aefs完成签到,获得积分20
7秒前
雪花发布了新的文献求助10
7秒前
小飞飞完成签到,获得积分10
7秒前
令狐梦安发布了新的文献求助10
9秒前
小菜鸟完成签到 ,获得积分10
9秒前
晓舟发布了新的文献求助20
10秒前
10秒前
10秒前
美好乐松应助千颂七采纳,获得10
10秒前
11秒前
111完成签到,获得积分10
11秒前
12秒前
yupaopao发布了新的文献求助10
12秒前
聪明无敌小腚宝完成签到,获得积分10
13秒前
13秒前
隐形曼青应助zxx5313491采纳,获得10
13秒前
14秒前
北斗村的星完成签到,获得积分10
14秒前
kongbai完成签到 ,获得积分10
14秒前
丰富画笔发布了新的文献求助10
14秒前
刘茂甫发布了新的文献求助10
14秒前
暂时想不到昵称完成签到,获得积分10
15秒前
CipherSage应助Ting采纳,获得10
15秒前
是漏漏呀完成签到 ,获得积分10
15秒前
15秒前
ningmengcao完成签到,获得积分10
16秒前
时光完成签到,获得积分10
16秒前
篱笆外的猫完成签到,获得积分10
16秒前
SHUAI完成签到,获得积分10
17秒前
旭宝儿发布了新的文献求助20
17秒前
高分求助中
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Evolution 1500
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Gerard de Lairesse : an artist between stage and studio 670
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 550
Sport, Music, Identities 500
T/CAB 0344-2024 重组人源化胶原蛋白内毒素去除方法 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2986999
求助须知:如何正确求助?哪些是违规求助? 2647904
关于积分的说明 7153429
捐赠科研通 2281850
什么是DOI,文献DOI怎么找? 1210092
版权声明 592408
科研通“疑难数据库(出版商)”最低求助积分说明 590979